Fewer than one in 10 individuals eligible to benefit from obesity jabs including Wegovy can access them, states the World Health Organization as it issues its initial recommendations on the medications.
With in excess of 1,000,000,000 people worldwide currently obese, it is advocating for broader and more equitable availability to this class of drugs.
Based on projections, more than two billion will be living with obesity by 2030 without intervention.
"The latest guidance recognises that excess weight is a long-term condition that can be managed with holistic and ongoing support," remarked WHO director-general Tedros Adhanom Ghebreyesus.
Substantial prices, limited production capacity, and distribution challenges are key obstacles to universal availability to the treatments that can aid individuals in losing substantial weight, explains the organization.
GLP-1 Therapy Shortage
Even in the present most optimistic outlook, the supply of these medications would only suffice for about 100 million people – fewer than 10% of the global need, as stated by the WHO.
The guideline encourages nations and manufacturers to widen access, by measures like patent sharing.
The intellectual property rights on the active ingredient – the primary component of a leading brand – is set to lapse in a number of nations in 2026.
The Way Obesity Drugs Function
The injections replicate a body's own hormone to reduce digestion speed, suppress the appetite and enhance satiety so individuals reduce food intake.
Individuals commonly start to lose weight in the initial weeks of starting on the regular doses.
Research suggests users may see weight return within a year of halting the drug, because their normal hunger resume.
To be carrying excess weight raises your chance for contracting diseases, such as type 2 diabetes, heart disease, stroke, and some malignancies.
Obesity impacts people in all nations and was associated with millions of fatalities worldwide in 2024, per the WHO.
